Interleukin-6 induces G1 arrest through induction of p27Kip1, a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells

被引:97
作者
Mori, S [1 ]
Murakami-Mori, K [1 ]
Bonavida, B [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA
关键词
D O I
10.1006/bbrc.1999.0515
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate carcinoma cells express high levels of interleukin-g (IL-6) and IL-6 receptor. In this study, we examined the effect of IL-6 on LNCaP human prostate carcinoma cells. IL-6 induces G(1) growth arrest of LNCaP. Following IL-6 treatment of LNCaP, Western blot analysis showed that the protein levels of cyclin-dependent kinase-2 (CDK2), CDK4, and CDK6 were decreased, while accumulation of CDK inhibitor p27(Kip1) was rapidly and markedly induced. In vitro kinase assays revealed that the CDK-associated histone H1 and CDK4- and CDK6-associated pRb kinase activities were significantly inhibited in IL-6-treated LNCaP. Further, a significant amount of p27(Kip1) was co-precipitated with CDK2, CDK4 and CDK6, as detected in immunoprecipitation experiments. Thus, IL6-induced G(1) arrest appears to be due to the accumulation of p27(Kip1). In addition, IL-6-treated LNCaP cells induced neuron-like morphological changes. Since neuroendocrine differentiation is observed in most prostate carcinomas, these findings raise the possibility that IL-6 may be involved in neuroendocrine differentiation in vivo. (C) 1999 Academic Press.
引用
收藏
页码:609 / 614
页数:6
相关论文
共 40 条
[31]   CALCITONIN STIMULATES GROWTH OF HUMAN PROSTATE-CANCER CELLS THROUGH RECEPTOR-MEDIATED INCREASE IN CYCLIC ADENOSINE 3',5'-MONOPHOSPHATES AND CYTOPLASMIC CA2+ TRANSIENTS [J].
SHAH, GV ;
RAYFORD, W ;
NOBLE, MJ ;
AUSTENFELD, M ;
WEIGEL, J ;
VAMOS, S ;
MEBUST, WK .
ENDOCRINOLOGY, 1994, 134 (02) :596-602
[32]   Cancer cell cycles [J].
Sherr, CJ .
SCIENCE, 1996, 274 (5293) :1672-1677
[33]  
SIEGALL CB, 1990, CANCER RES, V50, P7786
[34]   INTERLEUKIN-6 RECEPTOR MESSENGER-RNA IN PROSTATE CARCINOMAS AND BENIGN PROSTATE HYPERPLASIA [J].
SIEGSMUND, MJ ;
YAMAZAKI, H ;
PASTAN, I .
JOURNAL OF UROLOGY, 1994, 151 (05) :1396-1399
[35]  
STEINMAN RA, 1994, ONCOGENE, V9, P3389
[36]  
Taga T, 1996, J NEUROCHEM, V67, P1
[37]   INTERLEUKIN-6 - A CANDIDATE MEDIATOR OF HUMAN PROSTATE-CANCER MORBIDLTY [J].
TWILLIE, DA ;
EISENBERGER, MA ;
CARDUCCI, MA ;
HSEIH, WS ;
KIM, WY ;
SIMONS, JW .
UROLOGY, 1995, 45 (03) :542-549
[38]  
Wang QM, 1997, CANCER RES, V57, P2851
[39]  
WANG QM, 1996, CANC RES, V56
[40]   WILD-TYPE P53 INDUCES APOPTOSIS OF MYELOID LEUKEMIC-CELLS THAT IS INHIBITED BY INTERLEUKIN-6 [J].
YONISHROUACH, E ;
RESNITZKY, D ;
LOTEM, J ;
SACHS, L ;
KIMCHI, A ;
OREN, M .
NATURE, 1991, 352 (6333) :345-347